Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
It blocks the reward that makes the evening glass automatic, so the first pour is easier to leave at one and the ritual slowly loses its pull
What started as a market barely worth $1 billion in 2020 is now on track to hit a staggering $100 billion by 2030
For weight loss, it usually must be purchased privately
Lawsuits filed against businesses selling compounded injectables for diabetes and weight-loss Novo Nordisk and Eli Lilly, who developed and won FDA approval for their blockbuster weight-loss and diabetes medicines, Ozempic, Wegovy, Mounjaro and Zepbound, have been suing businesses who they say are marketing compounded versions of these drugs with false claims
Some Anthem plans cover this indication when they exclude "weight loss." See our complete OSA coverage guide Other options if coverage isn't available: Self-pay via LillyDirect: Single-dose vials at $299/month (2.5mg) to $449/month (higher doses)prices reduced in late 2025 [11] Zepbound Cost Guide TrumpRx.gov: ~$346/month for Zepbound (launched Feb 5, 2026) [15] Foundayo: Eli Lilly's oral GLP-1 tablet (FDA approved April 1, 2026)no injections, may have different coverage Compare medications: Wegovy, Mounjaro & more Alternatives Guide Switch plans: Check other insurers during open enrollment WHAT'S CHANGING 2026 Outlook Major developments are reshaping GLP-1 access in 2026
US$ 24.94
US$ 24.67
US$ 26.07
US$ 20.79
US$ 24.25
US$ 26.76
US$ 24.59
US$ 22.52
US$ 21.08
US$ 26.88
US$ 22.09
